Skip to main content

Table 2 Treatment cycles with hematological toxicities and non-hematological toxicities (50 patient-cycles)

From: A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma

Toxicity, n (%)

Grade 3

Grade 4

Hematologic

 Neutropenia

5 (10.0)

41 (82.0)

 Anemia

39 (78.0)

1 (2.0)

 Thrombocytopenia

4 (8.0)

46 (92.0)

Non-hematologic

 Sepsis*

0 (0.0)

1 (2.0)

 Febrile neutropenia

10 (20.0)

0 (0.0)

 Cytomegalovirus infection

2 (4.0)

0 (0.0)

 Hypokalemia

1 (2.0)

0 (0.0)

 Hemothorax

0 (0.0)

1 (2.0)

 Hyperamylasemia

2 (4.0)

0 (0.0)

  1. *The causative organism of sepsis was Bacillus spp